106 related articles for article (PubMed ID: 16316856)
21. Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors.
Kirk NS; Bezos A; Willis AC; Sudta P; Suksamrarn S; Parish CR; Ranson M; Kelso MJ
Bioorg Med Chem Lett; 2016 Apr; 26(7):1813-6. PubMed ID: 26912111
[TBL] [Abstract][Full Text] [Related]
22. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Ning S; Laird D; Cherrington JM; Knox SJ
Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
[TBL] [Abstract][Full Text] [Related]
23. Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416.
Honda M; Asai T; Umemoto T; Araki Y; Oku N; Tanaka M
Arch Ophthalmol; 2011 Mar; 129(3):317-21. PubMed ID: 21402988
[TBL] [Abstract][Full Text] [Related]
24. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
Cooney MM; Tserng KY; Makar V; McPeak RJ; Ingalls ST; Dowlati A; Overmoyer B; McCrae K; Ksenich P; Lavertu P; Ivy P; Hoppel CL; Remick S
Cancer Chemother Pharmacol; 2005 Mar; 55(3):295-300. PubMed ID: 15538570
[TBL] [Abstract][Full Text] [Related]
25. Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416.
Ye C; Sweeny D; Sukbuntherng J; Zhang Q; Tan W; Wong S; Madan A; Ogilvie B; Parkinson A; Antonian L
Toxicol In Vitro; 2006 Mar; 20(2):154-62. PubMed ID: 16321501
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin.
Overmoyer B; Fu P; Hoppel C; Radivoyevitch T; Shenk R; Persons M; Silverman P; Robertson K; Ziats NP; Wasman JK; Abdul-Karim FW; Jesberger JA; Duerk J; Hartman P; Hanks S; Lewin J; Dowlati A; McCrae K; Ivy P; Remick SC
Clin Cancer Res; 2007 Oct; 13(19):5862-8. PubMed ID: 17908980
[TBL] [Abstract][Full Text] [Related]
27. A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
Etienne-Grimaldi MC; Renée N; Izzedine H; Milano G
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(29):3757-61. PubMed ID: 19797000
[TBL] [Abstract][Full Text] [Related]
28. Isomerization of aldehyde-2,4-dinitrophenylhydrazone derivatives and validation of high-performance liquid chromatographic analysis.
Uchiyama S; Ando M; Aoyagi S
J Chromatogr A; 2003 May; 996(1-2):95-102. PubMed ID: 12830911
[TBL] [Abstract][Full Text] [Related]
29. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Minkin P; Zhao M; Chen Z; Ouwerkerk J; Gelderblom H; Baker SD
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Oct; 874(1-2):84-8. PubMed ID: 18823825
[TBL] [Abstract][Full Text] [Related]
30. Counter-current chromatographic estimation of hydrophobicity of Z-(cis) and E-(trans) enalapril and kinetics of cis/trans isomerization.
Shoji A; Yanagida A; Shindo H; Ito Y; Shibusawa Y
J Chromatogr A; 2007 Jul; 1157(1-2):101-7. PubMed ID: 17467722
[TBL] [Abstract][Full Text] [Related]
31. Stereoselective disposition of the geometric isomers of a novel lipoxygenase cyclo-oxygenase inhibitor in dog and photochemical interconversion of its isomers.
Matuszewski BK; Kanovsky SM; Constanzer ML; Yeh KC; Bayne WF
J Pharm Sci; 1988 Oct; 77(10):880-4. PubMed ID: 3148710
[TBL] [Abstract][Full Text] [Related]
32. Photoisomerization of alfa calcidol by a sensitized quantum chain reaction.
Estruch GA; Aramendía PF
Photochem Photobiol; 2012; 88(4):769-73. PubMed ID: 22128780
[TBL] [Abstract][Full Text] [Related]
33. Preformulation studies on the S-isomer of oxybutynin hydrochloride, an Improved Chemical Entity (ICE).
Luner PE; Kirsch LE; Majuru S; Oh E; Joshi AB; Wurster DE; Redmon MP
Drug Dev Ind Pharm; 2001 Apr; 27(4):321-9. PubMed ID: 11411899
[TBL] [Abstract][Full Text] [Related]
34. The reaction of azoles with 17-chloro-16-formylandrosta-5,16-dien-3β-yl-acetate: synthesis and structural elucidation of novel 16-azolylmethylene-17-oxoandrostanes.
Moreira VM; Salvador JA; Beja AM; Paixão JA
Steroids; 2011 May; 76(6):582-7. PubMed ID: 21352841
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and receptor binding affinity of both E- and Z-dehydrophenylalanine4 enkephalins.
Nitz TJ; Shimohigashi Y; Costa T; Chen HC; Stammer CH
Int J Pept Protein Res; 1986 May; 27(5):522-9. PubMed ID: 3015812
[TBL] [Abstract][Full Text] [Related]
36. Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials.
Sistla A; Sunga A; Phung K; Koparkar A; Shenoy N
Drug Dev Ind Pharm; 2004 Jan; 30(1):19-25. PubMed ID: 15000426
[TBL] [Abstract][Full Text] [Related]
37. SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction.
de Raaf MA; Schalij I; Gomez-Arroyo J; Rol N; Happé C; de Man FS; Vonk-Noordegraaf A; Westerhof N; Voelkel NF; Bogaard HJ
Eur Respir J; 2014 Jul; 44(1):160-8. PubMed ID: 24791833
[TBL] [Abstract][Full Text] [Related]
38. Biotransformation of the anti-angiogenic compound SU5416.
Antonian L; Zhang H; Yang C; Wagner G; Shawver LK; Shet M; Ogilvie B; Madan A; Parkinson A
Drug Metab Dispos; 2000 Dec; 28(12):1505-12. PubMed ID: 11095590
[TBL] [Abstract][Full Text] [Related]
39. Identification of a new isomer from a reversible isomerization of ceftriaxone in aqueous solution.
Tian Y; Lu L; Chang Y; Zhang DS; Li J; Feng YC; Hu CQ
J Pharm Biomed Anal; 2015 Jan; 102():326-30. PubMed ID: 25459931
[TBL] [Abstract][Full Text] [Related]
40. Photoregulation of α-Chymotrypsin Activity by Spiropyran-Based Inhibitors in Solution and Attached to an Optical Fiber.
Zhang X; Heng S; Abell AD
Chemistry; 2015 Jul; 21(30):10703-13. PubMed ID: 26100654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
